Hanshang Group (600774.SH) released its 2024 half-yearly report on August 15. During the reporting period, revenue was ¥626 million, a decrease of 10.74% year-on-year; net income attributable to shareholders of the listed company was ¥8.5108 million, a decrease of 82.35% year-on-year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -¥4.0843 million; basic earnings per share were ¥0.0288.

The main factors that affected performance are: the subsidiary Dikang Pharmaceuticals was influenced by factors such as centralized procurement and the rise in the price of medicinal materials, resulting in reduced profits; the subsidiary Dikang Traditional Chinese Medicine Pharmaceutical resumed operations this year, but its pharmaceutical sales revenue was low during the first half of the year, with high fixed expenses; the profitability of the commercial sector declined due to adjustments, which led to reduced profits.